Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

por Jordan, Nicola J, Dutkowski, Carol M, Barrow, Denise, Mottram, Huw J, Hutcheson, Iain R, Nicholson, Robert I, Guichard, Sylvie M, Gee, Julia MW
Publicado 2014

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

por Caligiuri, Maureen, Williams, Grace L., Castro, Jennifer, Battalagine, Linda, Wilker, Erik, Yao, Lili, Schiller, Shawn, Toms, Angela, Li, Ping, Pardo, Eneida, Graves, Bradford, Azofeifa, Joey, Chicas, Agustin, Herbertz, Torsten, Lai, Maria, Basken, Joel, Wood, Kenneth W., Xu, Qunli, Guichard, Sylvie M.
Publicado 2023

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

por de la Fuente, Macarena I, Colman, Howard, Rosenthal, Mark, Van Tine, Brian A, Levacic, Danijela, Walbert, Tobias, Gan, Hui K, Vieito, Maria, Milhem, Mohammed M, Lipford, Kathryn, Forsyth, Sanjeev, Guichard, Sylvie M, Mikhailov, Yelena, Sedkov, Alexander, Brevard, Julie, Kelly, Patrick F, Mohamed, Hesham, Monga, Varun
Publicado 2022

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-a...

por Fu, Xiaoyong, Creighton, Chad J, Biswal, Nrusingh C, Kumar, Vijetha, Shea, Martin, Herrera, Sabrina, Contreras, Alejandro, Gutierrez, Carolina, Wang, Tao, Nanda, Sarmistha, Giuliano, Mario, Morrison, Gladys, Nardone, Agostina, Karlin, Kristen L, Westbrook, Thomas F, Heiser, Laura M, Anur, Pavana, Spellman, Paul, Guichard, Sylvie M, Smith, Paul D, Davies, Barry R, Klinowska, Teresa, Lee, Adrian V, Mills, Gordon B, Rimawi, Mothaffar F, Hilsenbeck, Susan G, Gray, Joe W, Joshi, Amit, Osborne, C Kent, Schiff, Rachel
Publicado 2014